Klin Farmakol Farm. 2011;25(3):137-141

Adverse drug reactions specific to childhood

Petra Langerová1, Jiřina Zapletalová2, Karel Urbánek1
1 Ústav farmakologie LF UP a FN Olomouc
2 Dětská klinika LF UP a FN Olomouc

Good knowledge of adverse drug reactions (ADRs) is crucial for safe use of medication. ADRs are a common clinical problem in both

pediatric and adult medicine that can lead to significant morbidity. More than 9 % of hospitalized children suffer some adverse reactions

to therapy and up to 4 % of all their hospital admissions are caused by ADRs. The toxicity of many medicines in children is different to

that seen in adults. Indeed, there are some groups of pediatric patients, such as neonates, in whom drug toxicity appears to be relatively

common. About 70 % of drugs prescribed to the pediatric population are prescribed off-label. The risk of adverse drug reactions with such

prescribing is 3,6-fold higher in the hospital setting and 2-fold higher in the outpatient setting compared to on-label prescribing. Most of

the ADRs in children are similar to ADRs in adults. In this paper, ADRs specific for the pediatric population are discussed: Reye’s syndrome,

Gray baby syndrome, quinolone arthropathy, tooth discoloration, growth disorders, psychiatric disorders and others.

disorders, psychiatric disorders, acute agitation.

Keywords: children, adverse drug reactions, Reye’s syndrome, chloramphenicol, grey syndrome, quinolones, tetracyclines, growth

Published: December 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Langerová P, Zapletalová J, Urbánek K. Adverse drug reactions specific to childhood. Klin Farmakol Farm. 2011;25(3):137-141.
Download citation

References

  1. Imti Choonara I, Rieder MJ. Drug Toxicity and Adverse Drug Reactions in Children. Paediatric and Perinatal Drug Therapy, 2002; 5(1): 12-18. Go to original source...
  2. Van den Anker JN. Developmental pharmacology. Dev Disabil Res Rev. 2010; 16(3): 233-238. Go to original source... Go to PubMed...
  3. Rhodin MM, Anderson BJ, Peters AM, Coulthard MG, Wilkins B, et al. Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr Nephrol. 2009; 24(1): 67-76. Go to original source... Go to PubMed...
  4. Johnson TN. The development of drug metabolising enzymes and their influence on the susceptibility to adverse drug reactions in children. Toxicology. 2003; 192(1): 37-48. Go to original source... Go to PubMed...
  5. Clavenna A, Bonati M. Adverse drug reactions in childhood: a review of prospective studies and safety alerts. Arch Dis Child. 2009; 94(9): 724-728. Go to original source... Go to PubMed...
  6. Napoleone E. Children and ADRs (Adverse Drug Reactions). Ital J Pediatr. 2010; 36: 4. Go to original source... Go to PubMed...
  7. Kimland E, Rane A, Ufer M, Panagiotidis G. Paediatric adverse drug reactions reported in Sweden from 1987 to 2001. Pharmacoepidemiol Drug Saf. 2005; 14(7): 493-499. Go to original source... Go to PubMed...
  8. Le J, Nguyen T, Law AV, Hodding J. Adverse drug reactions among children over a 10-year period. Pediatrics. 2006; 118(2): 555-562. Go to original source... Go to PubMed...
  9. Star K, Norén GN, Nordin K, Edwards IR. Suspected Adverse Drug Reactions Reported For Children Worldwide: An Exploratory Study Using VigiBase. Drug Saf. 2011; 34(5): 415-428. Go to original source... Go to PubMed...
  10. Gosalakkal JA, Kamoji V. Reye syndrome and reye-like syndrome. Pediatr Neurol. 2008; 39(3): 198-200. Go to original source... Go to PubMed...
  11. Beutler AI, Chesnut GT, Mattingly JC, Jamieson B. FPIN's Clinical Inquiries. Aspirin use in children for fever or viral syndromes. Am Fam Physician. 2009; 80(12): 1472. Go to PubMed...
  12. Pugliese A, Beltramo T, Torre D. Reye's and Reye's-like syndromes. Cell Biochem Funct. 2008; 26(7): 741-746. Go to original source... Go to PubMed...
  13. Thomas L. Clinical Laboratory Diagnostics: Use and Assessment of Clinical Laboratory Results. TH-Books-Verl.-Ges., Frankfurt/Main, 1998.
  14. Mulhall A, de Louvois J, Hurley R. Chloramphenicol toxicity in neonates: its incidence and prevention. Caldwell PH, Murphy SB, Butow PN, Craig JC. Clinical trials in children. Lancet. 2004; 364(9436): 803-811. Go to original source... Go to PubMed...
  15. Kriška M, a kol. Riziko liekov v medicinskej praxi. Prvé vydanie. Bratislava; Slovak Academic Press, spol. s.r.o., 2000.
  16. Dukes MNG, Aronson JK, eds. Meyler's Side Effects of Drugs. 14th ed. New York; Elesevier, 2000.
  17. Sweetman SC ed. Martindale: The Complete Drug Reference. 35th ed. London; Pharmaceutical Press, 2007.
  18. Brunton LL, Lazo JS, Parker KL. Godman & Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York; McGraw-Hill Companies, 2006.
  19. Sendzik J, Lode H, Stahlmann R. Quinolone-induced arthropathy: an update focusing on new mechanistic and clinical data. Int J Antimicrob Agents. 2009; 33(3): 194-200. Go to original source... Go to PubMed...
  20. Burkhardt JE, Walterspiel JN, Schaad UB. Quinolone arthropathy in animals versus children. Clin Infect Dis. 1997; 25(5): 1196-1204. Go to original source... Go to PubMed...
  21. Hampel B, Hullmann R, Schmidt H. Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use-safety report. Pediatr Infect Dis J. 1997; 16(1): 127-129. Go to original source... Go to PubMed...
  22. Hoes JN, Jacobs JW, Boers M, Boumpas D, Buttgereit F. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2007; 66(12): 1560-1567. Go to original source... Go to PubMed...
  23. Heuschkel R, Salvestrini C, Beattie RM, Hildebrand H, Walters T, Griffiths A. Guidelines for the management of growth failure in childhood inflammatory bowel disease. Inflamm Bowel Dis. 2008; 14(6): 839-849. Go to original source... Go to PubMed...
  24. Koblížek V, Sedlák V. Použití inhalačních kortikosteroidů u různých typů bronchiálních obstrukcí. Klin Farmakol Farm 2010; 24(2): 80-84.
  25. Sharek PJ, Bergman DA. The effect of inhaled steroids on the linear growth of children with asthma: a meta-analysis. Pediatrics. 2000; 106(1): 8. Go to original source... Go to PubMed...
  26. Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med. 2000; 343(15): 1064-1069. Go to original source... Go to PubMed...
  27. Rachelefsky G. Inhaled corticosteroids and asthma control in children: assessing impairment and risk. Pediatrics. 2009; 123(1): 353-366. Go to original source... Go to PubMed...
  28. Grant LD. Research Strategies for Behavioral Teratology Studies. Environmental Health Perspectives 1976; 18: 85-94. Go to original source... Go to PubMed...
  29. Schneeweiss S, Patrick AR, Solomon DH, Dormuth CR, Miller M, Mehta J, Lee JC, Wang PS. Comparative safety of antidepressant agents for children and adolescents regarding suicidal acts. Pediatrics. 2010; 125(5): 876-888. Go to original source... Go to PubMed...
  30. Angela J. Dean PhD, Anna Hendy BPharm, Treasure McGuire PhD. Antidepressants in children and adolescents-changes in utilisation after safety warnings. Pharmacoepidemiol Drug Saf. 2007; 16: 1048-1053. Go to original source... Go to PubMed...
  31. Sikich N, Lerman J. Development and psychometric evaluation of the pediatric anesthesia emergence delirium scale. Anesthesiology. 2004; 100(5): 1138-1145. Go to original source... Go to PubMed...
  32. Manworren RC, Paulos CL, Pop R. Treating children for acute agitation in the PACU: differentiating pain and emergence delirium. J Perianesth Nurs. 2004; 19(3): 183-193. Go to original source... Go to PubMed...
  33. Bajwa SA, Costi D, Cyna AM. A comparison of emergence delirium scales following general anesthesia in children. Paediatr Anaesth. 2010; 20(8): 704-711. Go to original source... Go to PubMed...
  34. Wallerstedt SM, Brunlöf G, Sundström A, Eriksson AL. Montelukast and psychiatric disorders in children. Pharmacoepidemiol Drug Saf. 2009; 18(9): 858-864. Go to original source... Go to PubMed...
  35. Dreifuss FE, Santilli N, Langer DH, Sweeney KP, Moline KA, Menander KB. Valproic acid hepatic fatalities: a retrospective review. Neurology 1987; 37: 379-385. Go to original source... Go to PubMed...
  36. Konishi T, Naganuma Y, Hongo K, Murakami M, Yamatani M, Okada T. Carbamazepine induced skin rash in children with epilepsy. Eur J Pediatr 1993; 152: 605-608. Go to original source... Go to PubMed...
  37. Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. J Clin Invest 1988; 82: 1826-32. Go to original source... Go to PubMed...
  38. Mitchell P. Paediatric lamotrigine use hit by rash reports. Lancet 1997; 349: 1080. Go to original source...
  39. Besag F, McShane T, Neville B, Robinson R. Factors associated with serious skin reactions in children aged 12 years and under taking lamotrigine. Dev Med Child Neurol 1999; 41: 68-69. Go to original source... Go to PubMed...
  40. Bray RJ. Propofol infusion syndrome in children. Paediatric Anaesthesia 1998; 8: 491-499. Go to original source... Go to PubMed...




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.